Efficacy of intravenous parecoxib in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial - Summary - MDSpire

Efficacy of intravenous parecoxib in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial

  • By

  • Thanaput Kunlayawutipong

  • Tummarong Charoenrit

  • Tanawat Jongraksak

  • Thanawin Wong

  • Nisa Netinatsunton

  • Siriboon Attasaranya

  • Thanapon Yaowmaneerat

  • Jaksin Sottisuporn

  • Suraphon Assawasuwannakit

  • Siwanon Nawalerspanya

  • Surawitch Sawathanon

  • Pimsiri Sripongpun

  • Tanawat Pattarapuntakul

  • February 23, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy of intravenous parecoxib in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), specifically measuring the incidence rate of PEP as the primary outcome.

Key Findings:
  • Intravenous parecoxib significantly reduced the incidence of PEP (exact percentage reduction needed) compared to standard hydration alone.
  • The study demonstrated a notable reduction in post-ERCP abdominal pain in the parecoxib group.
  • No serious adverse events were reported related to parecoxib administration.
Interpretation:

Intravenous parecoxib may be an effective preventive intervention for PEP, particularly in patients at high risk for this complication, suggesting a need for its integration into clinical practice.

Limitations:
  • The study was conducted at a single center, which may limit generalizability and introduce potential biases.
  • The sample size and duration of follow-up may not be sufficient to capture all potential complications.
Conclusion:

Intravenous parecoxib is a promising option for reducing the incidence of PEP in patients undergoing ERCP, warranting further investigation in larger, multicenter trials to validate these findings.

Original Source(s)

Efficacy of intravenous parecoxib in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial

  • by Thanaput Kunlayawutipong, Tummarong Charoenrit, Tanawat Jongraksak, Thanawin Wong, Nisa Netinatsunton, Siriboon Attasaranya, Thanapon Yaowmaneerat, Jaksin Sottisuporn, Suraphon Assawasuwannakit, Siwanon Nawalerspanya, Surawitch Sawathanon, Pimsiri Sripongpun, Tanawat Pattarapuntakul

  • February 23, 2026

Related Content

Liposomal Bupivacaine Shows Limited Clinical Benefit After Third Molar Extraction

Extended-release anesthetic did not significantly improve postoperative pain, raising questions about its routine use in dental surgery.

Lumbar Fusion: Two Decades of Change

Investigators find rising use of complex lumbar fusion procedures and increasing hospital costs in the US.

Efficacy and safety of full-endoscopic sacroiliac joint denervation for the treatment of chronic low back pain: a systematic review